SUBSCRIBE
SUBSCRIBE
News   Drug Development

Synosia Therapeutics Announces Positive Interim Results for Potential First-in-Class Treatment for Parkinson’s Disease

February 1, 2010 | 
1 min read
Bookmark and Share

BASEL, Switzerland--(BUSINESS WIRE)--Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease.
Clinical research Phase 2 Europe
MORE ON THIS TOPIC
misty canyon with sharp cliff and lonely tree iin Delika
Neurodegeneration
Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%
October 30, 2026
 · 
2 min read
 · 
Gabrielle Masson
Robotic claw clutching a money stock illustration
Drug Development
Dren Bio lands $350M to push rare blood cancer therapy toward market
October 29, 2026
 · 
2 min read
 · 
Gabrielle Masson
pipeline infographic, industrial background, oil water gas transportation yellow pipes, plumbing system vector illustration
Earnings
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
October 29, 2026
 · 
4 min read
 · 
Gabrielle Masson
Target, miss the target, target shooting, dart, correct decisions, bow and arrow, dart on target, hits and misses (3d illustration)
Neuroscience
Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure
October 29, 2026
 · 
1 min read
 · 
Annalee Armstrong